Oregon Public Employees Retirement Fund Coherus Bio Sciences, Inc. Transaction History

Oregon Public Employees Retirement Fund

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 26, 2023	SELL	$3.79 - $8.3 $1,895 - $4,150	-500 Reduced 2.35%	20,810 $88,000
Q1 2023 May 04, 2023	SELL	$5.89 - $10.52 $353 - $631	-60 Reduced 0.28%	21,310 $145,000
Q4 2022 Jan 26, 2023	BUY	$5.69 - $10.07 $1,684 - $2,980	296 Added 1.4%	21,370 $0
Q2 2022 Jul 25, 2022	SELL	$5.86 - $13.23 $233,597 - $527,387	-39,863 Reduced 65.42%	21,074 $153,000
Q1 2022 Apr 21, 2022	SELL	$10.92 - $16.41 $5,460 - $8,205	-500 Reduced 0.81%	60,937 $787,000
Q4 2021 Feb 01, 2022	SELL	$15.81 - $18.99 $1.11 Million - $1.33 Million	-69,924 Reduced 53.23%	61,437 $981,000
Q3 2021 Oct 19, 2021	BUY	$12.68 - $17.79 $11,196 - $15,708	883 Added 0.68%	131,361 $2.11 Million
Q1 2021 Apr 20, 2021	BUY	$14.42 - $21.39 $14,275 - $21,176	990 Added 0.76%	130,478 $1.91 Million
Q4 2020 Feb 09, 2021	SELL	$16.56 - $18.94 $6,557 - $7,500	-396 Reduced 0.3%	129,488 $2.25 Million
Q3 2020 Nov 03, 2020	BUY	$17.41 - $19.89 $1.84 Million - $2.1 Million	105,584 Added 434.5%	129,884 $2.38 Million
Q2 2020 Jul 21, 2020	BUY	$14.43 - $19.16 $350,649 - $465,588	24,300 New	24,300 $434,000

136

78M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $86.3M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Oregon Public Employees Retirement Fund, based on Form 13F filings with the SEC.

Stay updated on Oregon Public Employees Retirement Fund with notifications on news.